argenx

argenx SE operates as a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. It operates from the Netherlands, Belgium, the United States of America, Japan, Switzerland, Germany and France. The firm partnering with academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. It evaluates efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Breda, the Netherlands.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. It operates through the following geographical segments: United States, Japan, EMEA, and China. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Amsterdam, the Netherlands.

July 30, 2020    Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced its half year 2020 financial results and provided a second quarter business update and outlook for the remainder of the year.

argenx reports half year 2020 financial results and provides second quarter business update

On Thursday, July 30, argenx (NASDAQ: ARGX) will release its latest earnings report.

Earnings Preview: argenx

argenx (ARGX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

argenx (ARGX): Strong Industry, Solid Earnings Estimate Revisions

Regulated information — Inside information

argenx announces full exercise of underwriters’ option to purchase additional ADSs

argenx raises $750 million in gross proceeds in a global offering

argenx's (ARGX) lead pipeline candidate, efgartigimod, meets primary endpoint in a pivotal study evaluating it in myasthenia gravis. A BLA is likely to be filed by the end of 2020.

argenx Up on Positive Data from Pivotal Efgartigimod Study

Positive pivotal trial results are giving investors a reason to cheer.

Here's Why argenx Stock Is Soaring Today

Regulated information – Inside information

argenx Announces Positive Topline Results from Phase 3 ADAPT Trial of Efgartigimod in Patients with Generalized Myasthenia Gravis

argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q1 2020 Results - Earnings Call Transcript

            - Topline data readout from Phase 3 ADAPT trial of efgartigimod in generalized myasthenia gravis on track for mid-2020 and Biologics License Application filing by end of year -             -  Enrollment paused in ongoing trials under Janssen and LEO Pharma collaborations  -                         - ARGX-117 being evaluated in COVID-19 patients with acute respiratory distress syndrome in collaboration with UZ Gent –

argenx reports first quarter 2020 financial results and provides business update

Ascendis Pharma

Axsome Therapeutics

Amicus Therapeutics

Iovance Biotherapeutics

Natera

United Therapeutics

Amid the COVID-19 pandemic, the investing pros say that it’s still possible to unmask names poised to take off on an upward trajectory.

7 “Strong Buy” Healthcare Stocks to Buy Now

Market Fairly Evaluates Argenx's Efgartigimod (ARGX-113) In Myasthenia Gravis

Argenx: The Upside Is Still There

argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q4 2019 Results - Earnings Call Transcript

Adient

Datadog

Kinsale Capital Group

Top Ranked Momentum Stocks to Buy for February 27th

argenx reports full year 2019 financial results and provides fourth quarter business update

argenx (ARGX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for argenx (ARGX)?

bluebird bio

Blueprint Medicines

Epizyme

Fate Therapeutics

Magenta Therapeutics Inc

The American Society of Hematology (ASH) hosted its 61st annual meeting, and one of the biggest biotech events, earlier this week in Orlando, Florida.

Wedbush’s Top Picks After ASH Annual Meeting

argenx  announces full exercise of underwriters’ option to purchase additional ADSs

argenx raises $484 million in gross proceeds in a global offering

Galapagos

Novocure

Biotechs trade on the prospects of new advancements to identify and treat diseases. That's something the world needs in good times and bad.

These 3 European Biotechs Can Help Recession-Proof Your Portfolio

Shares have risen by 385% since my initial recommendation and by 120% since my last update.

Revisiting argenx: Leader In FcRn Space Offers Upside Potential In 2020 And Beyond

argenx to Present at Morgan Stanley 17th Annual Global Healthcare Conference

argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q2 2019 Results - Earnings Call Transcript

Does ARGENX SE-ADR (ARGX) have what it takes to be a top stock pick for momentum investors? Let's find out.

News for argenx Stock (ARGX)